2019 Press releases

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder - February 22, 2019

Members of the media seeking further information may contact:
Catherine Baril
Senior Director, HR and Administration, Human Resources
TEL: 514-894-2777


You are now leaving , Lundbeck Canada’s Web site. Links to site outside of Lundbeck Canada are provided as resources to visitors and may not represent Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility in the content of linked sites.